Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Business Wire
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) (“Corvus”) on behalf of the company’s shareholders.The investigation seeks to determine whether Corvus and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s investors in connection with recent corporate actions.Corvus shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or by copying and pasting the link into your browser):https://kaskelalaw.com/case/corvus-pharmaceuticals/Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additio
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - Regulatory Support Drives Fast-Track Development of Novel T Cell Lymphoma Drugs from Eisai, Takeda, and Rhizen Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024GlobeNewswire
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.MarketBeat
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
CRVS
Earnings
- 8/6/24 - Beat
CRVS
Sec Filings
- 10/23/24 - Form 8-K
- 8/16/24 - Form EFFECT
- CRVS's page on the SEC website